Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to the

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to the

Zouhair Souissi

19 janvier 2022

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial – JAMA Editorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay

The post RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone. appeared first on Links Medicus.

Lu 529 fois